Puretech showcases differentiated development strategy, including new patient preference insights, and spotlights phase 2b data positioning deupirfenidone as a potential new standard of care in ipf

Boston--(business wire)--puretech demonstrates strategic and scientific leadership in idiopathic pulmonary fibrosis at 2025 ipf summit.

PRTC Ratings Summary

PRTC Quant Ranking